Every 8-K that EBR SYS INC (EBRCZ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EBRCZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EBRCZ filings page.
EBR Systems, Inc. (EBRCZ) reported a leadership transition in its commercial organization. The company announced the impending departure of Chief Commercial Officer Erik Strandberg, who will leave in the coming months, with his final date still to be determined. EBR states that his departure is not due to any dispute or disagreement regarding operations, policies or practices. President and Chief Executive Officer John McCutcheon will assume responsibility for the commercial organization while a search is conducted for a successor Chief Commercial Officer. EBR indicated it expects to enter into a separation agreement with Mr. Strandberg and plans to disclose its material terms in a future amendment. In an accompanying press release, the company stated it does not expect any negative impact on U.S. commercial adoption from this change and plans to focus on accelerating training requirements in the field team to support ongoing and increasing clinical demand for its WiSE wireless cardiac pacing technology.
EBR Systems, Inc. (EBRCZ) reported the results of a Special Meeting of Stockholders held on August 18, 2026. Stockholders ratified the prior issuance of 77,352,890 CDIs (7,735,289 shares of common stock) at A$0.38 per CDI under ASX Listing Rule 7.4.
Stockholders also approved a new issuance of 92,105,270 CDIs (9,210,527 shares) at A$0.38 per CDI to certain clients of BCP3 Pty Ltd, an associate of non-executive director Dr. Chris Nave, under ASX Listing Rule 10.11. A proposal to permit adjournment of the Special Meeting, if needed to solicit additional proxies, was also approved.
EBR Systems, Inc. entered into an underwriting agreement for a fully underwritten A$150.0 million capital raise via the sale of approximately 394.7 million new CHESS Depository Interests (CDIs) on the ASX at A$0.38 per CDI, with ten CDIs representing one common share.
The structure includes an A$64.4 million institutional placement and an A$85.6 million 1-for-2 pro rata accelerated non-renounceable entitlement offer. The institutional placement and institutional entitlement offer are completed, while a conditional A$35.0 million tranche and a A$43.6 million retail entitlement offer remain subject to securityholder approval and future settlement. The offer price reflects discounts to recent trading prices and theoretical ex-rights price.
EBR Systems, Inc. reported the results of its 2026 annual stockholder meeting held via webcast. Stockholders elected Class II directors John McCutcheon and Bronwyn Evans to serve until the 2029 annual meeting.
They also approved adding 18,010,366 shares of common stock to the 2021 Equity Incentive Plan under its evergreen provision and ratified multiple option grants to directors and related entities. These grants include options valued at US$716,154 for John McCutcheon, US$160,000 for Allan Will, and several US$130,000 awards for other directors and their nominated entities, all under Australian Securities Exchange listing rules.
EBR Systems, Inc. furnished an update highlighting strong early commercial adoption of its WiSE wireless cardiac pacing system and preliminary Q1 2026 results. The company completed its 71st commercial implant, including 41 commercial patients in Q1 2026, more than double the prior quarter’s case count.
During Q1 2026, EBR signed 16 additional purchase agreements with target centres, bringing the total to 37, and expanded its implanter base to 55 trained physicians, with 22 trained in the quarter. The company also implemented a 1-for-10 reverse stock split of its common stock effective April 1, 2026, while changing its CDI conversion ratio to 10:1 without altering individual ownership ratios.
Management will discuss these commercial and clinical developments, along with preliminary unaudited Q1 2026 financial information, on an investor webinar scheduled for April 10, 2026 at 09:00am AEST. All financial figures remain preliminary and unaudited pending completion of the quarter-end close and review procedures.
EBR Systems, Inc. approved and implemented a 1-for-10 reverse stock split of its common stock, effective April 1, 2026 at 4:00 a.m. Eastern Time. Every 10 issued and outstanding shares will automatically convert into 1 share, with fractional shares rounded up to the nearest whole share.
The amendment does not change the number of authorized common shares or their par value. CHESS Depositary Interests will not be consolidated; instead, the CDI-to-share conversion ratio will shift from 1:1 to 10:1, with no anticipated change in CDI value apart from minor rounding effects.
On the ASX, March 30, 2026 (Australian time) will be the last trading day on a pre-split 1:1 basis, and March 31, 2026 will be the first trading day on a deferred settlement basis using the new 10:1 conversion ratio.
EBR Systems, Inc. reported that stockholders approved all three proposals at a virtual special meeting held on March 11, 2026. Investors authorized a reverse stock split of the company’s common stock at a ratio between 1-for-5 and 1-for-20, to be implemented at the board’s discretion, with 233,231,110 votes in favor and 970,364 against.
Stockholders also ratified the prior issuance of 55,900,000 CHESS Depositary Interests (equivalent to 55,900,000 common shares) at an issue price of A$1.00 per CDI under ASX Listing Rule 7.4, and approved a potential adjournment of the meeting if additional proxy solicitations had been needed.
EBR Systems, Inc. filed a current report to share that it has issued a press release describing its commercial and clinical progress and preliminary financial results for the fourth quarter and full year ended December 31, 2025. The company noted that the press release, dated January 12, 2026, includes early estimates only, which are unaudited and may change once normal closing and audit procedures are completed.
The press release, titled “EBR Announces Strong Q4 FY 2025 Commercial and Clinical Progress,” is furnished as an exhibit and is not deemed filed for liability purposes under securities laws, nor automatically incorporated into other securities filings unless specifically referenced.